Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 19/20 | 0.52 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3819113 | 0.98 | GSK3B (0.51) | GSK3BCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL83555 | 0.83 | GSK3B (0.49) | GSK3BCDC7ROCK2MAP4K4HIPK2 | |
| SCHEMBL12207381 | 0.80 | GSK3B (0.52) | GSK3BCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL1673943 | 0.80 | GSK3B (0.52) | GSK3BCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL3804927 | 0.80 | GSK3B (0.56) | GSK3BCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL101767 | 0.80 | GSK3B (0.60) | GSK3B | |
| SCHEMBL3743033 | 0.78 | GSK3B (0.50) | GSK3BCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL2488368 | 0.76 | GSK3B (0.49) | GSK3BCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL7385338 | 0.76 | GSK3B (0.59) | GSK3BCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL81844 | 0.76 | GSK3B (0.50) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111349085-B | Pyrimidone compounds or pharmaceutically acceptable salts thereof, preparation method and application | 中国药科大学 | 2021-02-09 | — | — | CN | disclosed |
| CN-111349085-A | Pyrimidone compounds or pharmaceutically acceptable salts thereof, preparation method and application | 中国药科大学 | 2020-06-30 | — | — | CN | disclosed |
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| EP-1572681-B1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| WO-2006028290-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-16 | — | — | WO | disclosed |
| CN-1726209-A | 3-substituted-4-pyrimidone derivatives | SANOFI AVENTIS (JP) | 2006-01-25 | — | — | CN | disclosed |
| EP-1608630-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-1572681-A1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2005-09-14 | — | — | EP | disclosed |
| US-20050090490-A1 | 3-Substituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-04-28 | — | — | US | disclosed |
| CN-1556804-A | 3-substituted-4-pyrimidone derivatives | ������ҩ��ʽ���� | 2004-12-22 | — | — | CN | disclosed |
| WO-2004085408-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004055007-A1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-07-01 | — | — | WO | disclosed |
| EP-1427720-A1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003037888-A1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | PSEN1, PRNP, PSEN2 | GSK3B 256/4885CDC7 1782/4885ROCK2 884/4885 |
| US-20050090490-A1 | 3-Substituted-4-pyrimidone derivatives | CDK1, TTBK1, CDK2 | GSK3B 247/4885CDC7 1127/4885ROCK2 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.